Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Corcept Therapeutics (CORT) Accumulated Depreciation & Amortization (2016 - 2023)

Corcept Therapeutics' Accumulated Depreciation & Amortization history spans 13 years, with the latest figure at $358000.0 for Q2 2023.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 11.39% to $358000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $358000.0, a 11.39% decrease, with the full-year FY2022 number at $3.7 million, up 26.74% from a year prior.
  • Accumulated Depreciation & Amortization hit $358000.0 in Q2 2023 for Corcept Therapeutics, up from $172000.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for CORT hit a ceiling of $3.7 million in Q4 2022 and a floor of $172000.0 in Q1 2023.
  • Historically, Accumulated Depreciation & Amortization has averaged $1.0 million across 5 years, with a median of $447000.0 in 2020.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 582.6% in 2021 and later tumbled 83.65% in 2022.
  • Tracing CORT's Accumulated Depreciation & Amortization over 5 years: stood at $703000.0 in 2019, then surged by 163.58% to $1.9 million in 2020, then skyrocketed by 57.85% to $2.9 million in 2021, then grew by 26.74% to $3.7 million in 2022, then crashed by 90.34% to $358000.0 in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for CORT at $358000.0 in Q2 2023, $172000.0 in Q1 2023, and $3.7 million in Q4 2022.